Otonomy Announces Results of Phase 2a Trial for OTO-413
Otonomy, Inc announced positive top-line results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss.
Otonomy, Inc announced positive top-line results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss.
Otonomy intends to complete the clinical development to support registration of OTIVIDEX in the United States for patients with Ménière’s disease, and will advance multiple programs for the prevention and treatment of sensorineural hearing loss, and the treatment of tinnitus.